HIV Infections Clinical Trial
Official title:
Communication Technology to Disseminate Evidence-Based HIV Interventions to NGOs
This study will compare the effectiveness of face-to-face training versus Web-based training seminars in disseminating HIV prevention interventions to nongovernmental organizations in Eastern Europe and Central Asia.
An estimated total of 60 million people have been infected with HIV since the first cases
were reported in the early 1980s. Although the HIV/AIDS pandemic is a global crisis, certain
regions have been affected more than others. The Eastern European and Central Asian region,
in particular, has one of the fastest growing rates of HIV infections in the world. Most new
HIV infections in this region have been occurring among injection drug users, commercial sex
workers, and men who have sex with men, but the virus continues to increasingly affect the
general population, too. HIV prevention interventions that are able to be disseminated to a
large population are necessary. The Popular Opinion Leader (POL) intervention is an HIV
prevention program that recruits and trains opinion leaders in the community to promote safe
sex behaviors through risk-reduction conversations with peers. Administering the POL
intervention to nongovernmental organizations (NGOs) may be an effective means of assuring
that the intervention is extended throughout the region. However, the best means of
disseminating the POL program and assuring its full adoption by NGOs is unknown. This study
will compare the effectiveness of face-to-face training versus Web-based training seminars in
disseminating the POL intervention to NGOs in Eastern Europe and Central Asia.
Participation in this study will last 24 months. Potential NGOs will first undergo baseline
assessments that will include an in-depth 90-minute phone interview with the NGO director and
completion of attitude scales about the POL HIV intervention. NGOs will then be assigned
randomly to one of three study groups:
- Participating NGOs in Group 1 will receive the POL intervention through face-to-face
training. Staff will receive 2-day training on the POL intervention and individualized
telephone follow-up consultations concerning POL implementation.
- Participating NGOs in Group 2 will receive the POL intervention through Web-based
training. Staff will receive training delivered entirely by means of a Web-based,
distance learning curriculum. Staff will also be offered individualized telephone
follow-up consultations concerning POL implementation.
- Participating NGOs in Group 3 will receive no intervention.
All participating NGOs will undergo follow-up assessments 12 and 24 months after completing
the intervention training. Assessments will include a 90-minute phone interview with the NGO
director and a 10-minute phone interview with NGO staff members to assess attitudes
concerning the intervention, their adoption of the core elements of the intervention model,
and the extent of usage of training materials. A number of NGOs that report full adoption of
the POL intervention will be selected randomly to undergo a 2-day validation site visit by an
assessment team member. Site visits will be used to conduct interviews with NGO staff and the
opinion leaders, validate reports of intervention adoption, observe POL sessions, and review
materials used in training sessions.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |